register

News & Trends - MedTech & Diagnostics

First Australian medtech company secures US reimbursement

Health Industry Hub | February 10, 2023 |

MedTech News: A local medical device manufacturer has become the first Australian company to have its medical device receive reimbursement from Centres of Medicare and Medicaid Services (CMS) in the US.

Respiri can now have its patented wheezo device, used for remote patient monitoring (RPM) programs, receive reimbursement in the US.

The RPM program, delivered by Respiri’s partner Access Telehealth, includes patient engagement and remote monitoring using the Access cloud-based platform, Remotli.

“Receiving first reimbursement revenues for wheezo RPM in the US is a major commercialisation milestone for the company,” Respiri CEO Marjan Mikel said.

Although not currently financially material, the company said this event marks a key milestone in the execution of the company’s US business strategy.

Respiri currently generates monthly recurring revenues per patient when the wheezo RPM program is delivered and reimbursed by CMS, in addition to device sales.

“We are also proud to be the first Australian eHealth company whose device has been prescribed by physicians for RPM and successfully reimbursed. We continue to focus our efforts on scaling up operations to engage with and gain acceptance of the wheezo RPM product from both existing and new medical institutions by offering a new standard of care in the US medical industry,” said Mr Mikel.

The wheezo medical device is currently being used by 20 patients across several medical institutions which have engaged with Access Telehealth to use the wheezo RPM program for patients who suffer from respiratory disorders, including asthma and chronic obstructive pulmonary disease (COPD).

These numbers are expected to continue to grow as the wheezo RPM program gains traction in the US, with a further 500 patients already identified for onboarding in the short term.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Federal Health Minister succumbs to pressure, commits to extra meeting to clear PBAC backlog

Federal Health Minister succumbs to pressure, commits to extra meeting to clear PBAC backlog

Health Industry Hub | November 7, 2024 |

Pharma News: The Minister for Health and Aged Care, Mark Butler MP, has confirmed that the Pharmaceutical Benefits Advisory Committee […]

More


News & Trends - MedTech & Diagnostics

Medtech company partners with Aussie researchers in AI technology for GI cancer detection

Medtech company partners with Aussie researchers in AI technology for GI cancer detection

Health Industry Hub | November 7, 2024 |

MedTech & Diagnostics News: To develop a next-generation gastrointestinal (GI) flexible endomicroscope equipped with edge-artificial intelligence (AI) technology, Monash University’s […]

More


News & Trends - Pharmaceuticals

Local oncologists first to enrol prostate cancer patients in phase 3 theranostics trial

Local oncologists first to enrol prostate cancer patients in phase 3 theranostics trial

Health Industry Hub | November 7, 2024 |

Pharma News: GenesisCare oncologists have achieved a significant milestone, becoming the first to enrol and deliver patient treatment in a […]

More


Human Resources

Ipsen's culture of 'collaboration and diversity' earns Great Place to Work certification

Ipsen’s culture of ‘collaboration and diversity’ earns Great Place to Work certification

Health Industry Hub | November 6, 2024 |

Ipsen Australia and New Zealand has announced its certification as a Great Place to Work in 2024, joining 11 other […]

More


This content is copyright protected. Please subscribe to gain access.